A5088554079- HIV/AIDS Research and Interventions
- Viral Infections and Outbreaks Research
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV Research and Treatment
- Viral Infections and Vectors
- Vaccine Coverage and Hesitancy
- Hepatitis B Virus Studies
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Malaria Research and Control
- HIV/AIDS drug development and treatment
- Vector-Borne Animal Diseases
- Adolescent Sexual and Reproductive Health
- Ethics in Clinical Research
- HIV, Drug Use, Sexual Risk
- Reproductive tract infections research
- Hemoglobinopathies and Related Disorders
- Climate Change and Health Impacts
- Syphilis Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Immune Cell Function and Interaction
- Travel-related health issues
- Global Public Health Policies and Epidemiology
- Disaster Response and Management
- Nail Diseases and Treatments
London School of Hygiene & Tropical Medicine
2015-2024
Uganda Virus Research Institute
2013-2023
Medical Research Council
2022
University of London
2022
Government of Uganda
2021
MRC Clinical Trials Unit at UCL
2015-2016
University College London
2015-2016
Creative Commons
2015-2016
University of the Witwatersrand
2015-2016
Fundación Juan March
2016
Ebola vaccine development was accelerated in response to the 2014 virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimens Lake Victoria Basin Tanzania Uganda mid-level altitude, malaria-endemic settings.
Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness death thousands of adults children. The objective this study was assess safety, tolerability, immunogenicity the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimen adolescents children Africa.In multicentre, randomised, observer-blind, placebo-controlled Phase II study, 131 (12 17 years old) 132 (4 11 were enrolled from Eastern Western randomised 5:1 receive vaccines or placebo. Vaccine groups...
We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy HIV-infected adults with different intervals between vaccinations.
Background Cryptococcal meningitis (CCM) remains a leading cause of mortality amongst HIV infected patients in sub-Saharan Africa. When receive recommended therapy, at 10 weeks has been reported to vary between 20 36%. However, rate and factors affecting after completing therapy are not well known. We investigated rate, 2 years among CCM following completion Uganda. Methods A retrospective cohort study was conducted that had completed for (2 intravenous amphotericin B 1mg/kg oral Fluconazole...
A safe and effective vaginal microbicide could substantially reduce HIV acquisition for women. Consistent gel use is, however, of great importance to ensure continued protection against infection, even with a microbicide. We assessed the long-term correlates consistent in MDP 301 clinical trial among HIV-negative women sero-discordant couples south-west Uganda. living an HIV-infected partner were enrolled between 2005 2008, three-arm phase III randomized 2% PRO2000, 0.5% PRO2000 or placebo...
Background Cotrimoxazole (CTX) preventive therapy (CPT) reduces opportunistic infections and malaria in HIV-infected patients. In Africa, policies on sustained CPT during antiretroviral (ART) differ between countries. We assessed the safety of discontinuing stable patients ART Uganda. Methods COSTOP was a double-blind placebo-controlled trial. Patients aged ≥18 years, CPT, (CD4 counts ≥250 cells/μL); were randomised to daily oral placebo (PLC group) or cotrimoxazole 960 mg/tablet (CTX...
Previous unblinded trials have shown increased malaria among HIV-infected adults on antiretroviral therapy (ART) who stop cotrimoxazole (CTX) prophylaxis. We investigated the effect of stopping CTX in ART a double-blind, placebo-controlled trial.HIV-infected Ugandan stable and with CD4 cell count at least 250 cells/μl were randomized (1 : 1) to continue or receive matching placebo (COSTOP trial; ISRCTN44723643). Clinical was defined as fever positive blood slide, considered severe if...
Abstract Background Rift Valley fever (RVF) is a zoonotic viral disease of increasing intensity among humans in Africa and the Arabian Peninsula. In Uganda, cases reported prior to 2016 were mild or not fully documented. We report this paper on severe morbidity hospital-based mortality human Uganda. Methods Between November 2017 March 2020 Uganda Virus Research Institute (UVRI) confirmed by polymerase chain reaction (PCR). Ethical regulatory approvals obtained enrol survivors into one-year...
Cotrimoxazole (CTX) prophylaxis is recommended by the World Health Organisation for HIV infected persons. However, once patients have commenced ART in resource limited settings, benefits of continued CTX are not known. The few studies that investigated safety discontinuing these settings had limitations due to their design.COSTOP a randomised double blind placebo controlled non-inferiority trial among Ugandan adults stabilised on anti-retroviral treatment (ART). Participants with CD4 count...
Using the data of a trial on cotrimoxazole (CTX) cessation, we investigated effect different antiretroviral therapy (ART) regimens incidence clinical malaria.During cessation (ISRCTN44723643), HIV-infected Ugandan adults with CD4 at least 250 cells/μl were randomized to receive either CTX prophylaxis or placebo and followed for median 2.5 years. Blood slides malaria microscopy examined scheduled visits unscheduled when participant felt unwell. cell counts done 6-monthly. Malaria was defined...
The 2013-2016 Ebola epidemic in West Africa is the worst ever caused by Ebolaviruses with over 28,000 human cases and 11,325 deaths. World Health Organisation (WHO) declared a public health crisis that required accelerated development of novel interventions including vaccines. Medical Research Council/Uganda Virus Institute London School Hygiene Tropical Medicine Uganda Unit (MRC/UVRI & LSHTM Unit) was among African research sites implemented VAC52150EBL1004 vaccine trial.We report on...
Globally, early initiation of antiretroviral therapy for HIV led to a reduction in the estimated mortality from cryptococcal meningitis (CCM) 624,700 2009 181,100 2014. However, CCM remains one leading causes among infected patients especially sub-Saharan Africa where 75% deaths occur. Most studies evaluating have reported short-term (at or before 10 weeks therapy). We determined and associated factors treated CryptoDex trial (ISRCTN59144167) Uganda, effect dexamethasone adjunctive on at two...
The reasons why research participants join clinical trials remains an area of inquiry especially in low and middle income countries.
Abstract Background Cotrimoxazole preventive therapy (CPT) in human immunodeficiency virus (HIV) infection is a World Health Organization–recommended standard of care resource-limited settings, but the mechanism CPT’s beneficial effects unclear. The COSTOP trial (ISRCTN44723643) evaluated noninferiority discontinuing CPT stabilized patients on antiretroviral therapy. immunology substudy was conducted subset participants randomized to continue (n = 86) or discontinue (placebo, n as daily...
COSTOP was a randomised controlled trial designed to assess the risks and benefits HIV-infected participants stabilised on anti-retroviral treatment of stopping cotrimoxazole (CTX). In order extent which patients may have had access used CTX other than that supplied as study drug it decided conduct an exit interview. A structured interview administered by interviewers who were not associated with team in make easier for respond truthfully sensitive questions about adherence protocol. total...
This analysis evaluated the immune response to two-dose, heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen, administered 56-days apart, from multiple African sites based on results one analytic laboratory.
People living with HIV constitute an important part of the population in regions at risk Ebola virus disease outbreaks. The two-dose Ad26.ZEBOV, MVA-BN-Filo vaccine regimen induces strong immune responses HIV-positive (HIV+) adults but durability this response is unknown. It also unclear whether can establish memory to enable anamnestic upon re-exposure antigen.
Natural killer cells play an important role in the control of viral infections both by regulating acquired immune responses and as potent innate or antibody-mediated cytotoxic effector cells. NK have been implicated Ebola virus our previous studies European trial participants demonstrated durable activation, proliferation antibody-dependent cell activation after heterologous two-dose vaccination with adenovirus type 26.ZEBOV followed modified vaccinia Ankara-BN-Filo. Regional variation...
Use of a reliable contraception method has become an inclusion criterion in prevention trials to minimize time off product. We report on hormonal contraceptive prevalence, uptake, sustained use and correlates the Microbicides Development Programme (MDP 301) trial at Masaka Centre Uganda. HIV negative women sero-discordant relationships were enrolled followed-up for 52 104 weeks from 2005 2009. Contraceptive data was collected through self-report baseline dispensing records during follow-up....
The effect of CD4 count on malaria incidence in HIV infected adults antiretroviral therapy (ART) was assessed the context a randomized controlled trial stopping cotrimoxazole (CTX). This study presents sub-analysis COSTOP (ISRCTN44723643) which carried out among HIV-infected Ugandan stable ART with counts ≥250 cells/µl. Participants were (1:1) to continue CTX or stop and receive matching placebo, followed up for minimum 1 year (median 2.5 years). measured at baseline, 3 months then every 6...
Cryptococcal meningitis (CCM) remains one of the leading causes mortality among HIV infected patients. Due to factors such as severity CCM pathology, quality life (QOL) patients post-treatment is likely be poor. Few studies have reported on QOL post treatment completion. We used data collected in CryptoDex trial (ISRCTN59144167) determine and associated at week 10 six months from initiation.CryptoDex was a double-blind placebo-controlled adjunctive dexamethasone adults with CCM, conducted...